PCM
PBYI icon

Palisade Capital Management’s Puma Biotechnology PBYI Stock Holding History

Palisade Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-55,950
Closed -$6.53M – 560
2015
Q2 		$6.53M Buy
55,950
+14,621
+35% +$2.65M 0.17% 212
2015
Q1 		$9.76M Buy
41,329
+11,581
+39% +$2.48M 0.25% 148
2014
Q4 		$5.63M Buy
+29,748
New +$6.6M 0.14% 263

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $44.4B AUM 36.05% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Palisade Capital Management's PBYI Position: Q3 2015 in Review

Palisade Capital Management sold out of Puma Biotechnology (PBYI) in Q3 2015, closing a stake of 55,950 shares — an estimated $6.53M sold.

Palisade Capital Management first reported a position in PBYI in Q4 2014 and held it in 3 quarters. The position peaked at $9.76M in Q1 2015. 163 funds tracked by Wall St. Rank hold PBYI as of Q3 2015.

  • Palisade Capital Management reported no remaining Puma Biotechnology position as of Q3 2015 after selling out during the quarter.
  • Palisade Capital Management sold 55,950 Puma Biotechnology shares in Q3 2015, an estimated $6.53M.
  • Palisade Capital Management first reported a position in Puma Biotechnology in Q4 2014 and held it in 3 quarters.
  • Palisade Capital Management's Puma Biotechnology position peaked at $9.76M in Q1 2015.
  • 163 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2015.

Based on Palisade Capital Management's 13F filing for Q3 2015, filed 29 Oct 2015.